Status:

TERMINATED

Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Lead Sponsor:

Sanofi

Conditions:

Hypercholesterolemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia. T...

Detailed Description

The study will include a 2-week pre-randomization placebo lead-in phase and a double-blind treatment period of at least 12 months and can be variably extended up to approximately 18 months.

Eligibility Criteria

Inclusion

  • Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy

Exclusion

  • LDL-C levels \> 250 mg/dL (6.48 mmol/L)
  • Triglycerides levels \> 350mg/dL (3.95 mmol/L)
  • Conditions / situations such as:
  • presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels
  • Active liver disease
  • High estimated risk of Coronary Heart Disease
  • Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease
  • Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive
  • Pregnant or breast-feeding women,
  • Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product.
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2009

Estimated Enrollment :

826 Patients enrolled

Trial Details

Trial ID

NCT00718965

Start Date

July 1 2008

End Date

June 1 2009

Last Update

May 16 2016

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sanofi-Aventis Administrative Office

Bridgewater, New Jersey, United States, 08807

2

Sanofi-Aventis Administrative Office

San Juan, Puerto Rico